Inozyme Pharma, Inc. (INZY)
Automate Your Wheel Strategy on INZY
With Tiblio's Option Bot, you can configure your own wheel strategy including INZY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INZY
- Rev/Share 0.0
- Book/Share 0.4947
- PB 7.9848
- Debt/Equity 0.8293
- CurrentRatio 2.1888
- ROIC -1.3635
- MktCap 255019110.0
- FreeCF/Share -1.5021
- PFCF -2.6412
- PE -2.3792
- Debt/Assets 0.2771
- DivYield 0
- ROE -1.5997
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INZY | Raymond James | -- | Outperform | -- | $26 | Dec. 12, 2024 |
| Initiation | INZY | Stifel | -- | Buy | -- | $16 | Sept. 12, 2024 |
News
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 16, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Inozyme Pharma, Inc. (NASDAQ: INZY ), relating to the proposed merger with BioMarin Pharmaceutical Inc. Under the terms of the agreement, BioMarin will commence a cash tender offer to acquire all of the outstanding shares of Inozyme common stock at a price of $4.00 …
Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of Shareholders
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Charter Communications, Inc. (NASDAQ: CHTR)'s merger with Cox Communications. If you are a Charter shareholder, click here to learn more about your legal rights and options.
Read More
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inozyme Pharma, Inc. (NASDAQ: INZY) to BioMarin Pharmaceutical Inc. for $4.00 per share is fair to Inozyme shareholders. Halper Sadeh encourages Inozyme shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Inozyme a.
Read More
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Inozyme (Nasdaq: INZY) for possible breaches of fiduciary duty and other violations of law in its transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Inozyme will receive $4.00 per share in an all-cash transaction for a total consideration.
Read More
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif.
Read More
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company's Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida.
Read More
About Inozyme Pharma, Inc. (INZY)
- IPO Date 2020-07-24
- Website https://www.inozyme.com
- Industry Biotechnology
- CEO Dr. Douglas A. Treco Ph.D.
- Employees 67